/PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has...
Lille, France; Cambridge, MA; July 08, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives...
Quorum of 25.16% on first convening; allowing approval of all the resolutions submitted by the Board of Directors Lille, France; Cambridge, MA; May 25,...
Cash and cash equivalents totaled €222.2 million as of March 31, 2022 Lille, France; Cambridge, MA; May 11, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a...
Lille, France; Cambridge, MA; April 29, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives...
Lille, France; Cambridge, MA; April 20, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives...
GENFIT S.A. Unsponsored ADR (GNFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cash and cash equivalents totaled €258.8 million as of December 31, 2021Major financial achievements in 2021 include landmark strategic partnership deal...
Cash and cash equivalents totaled €258.8 million as of December 31, 2021, which includes the €120 million upfront payment and a €28 million equity...
Lille, France; Cambridge, MA; January 24, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...